Online inquiry

IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8704MR)

This product GTTS-WQ8704MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001178096.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2152
UniProt ID P13726
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8704MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11876MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ5840MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ4342MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ8686MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ6451MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P23
GTTS-WQ14725MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ561MR IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 4D5-8
GTTS-WQ15228MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TAK-079
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW